Abstract
Intermittent fasting has been shown to protect healthy cells from chemotherapy toxicity while sensitizing cancer cells, but the extent to which fasting is safe and feasible for individuals during chemotherapy is unknown. The studies reviewed demonstrate that for well-nourished women with breast cancer, intermittent fasting between 24 and 72 hours can be safe and feasible as determined by treatment side effects, blood work, adherence to a fasting protocol, and quality of life. Fasting is not without potential adverse side effects and limitations. Further research is needed to standardize optimal length of fasting and determine whether limited caloric intake is beneficial while fasting during chemotherapy.